Free Trial

Organon & Co. (OGN) Competitors

$20.98
+0.01 (+0.05%)
(As of 07/19/2024 ET)

OGN vs. TEVA, BGNE, RDY, CTLT, LNTH, RVMD, ELAN, SMMT, KRYS, and APLS

Should you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), Lantheus (LNTH), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Summit Therapeutics (SMMT), Krystal Biotech (KRYS), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry.

Organon & Co. vs.

Organon & Co. (NYSE:OGN) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Organon & Co. has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.

Teva Pharmaceutical Industries received 1301 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 67.68% of users gave Teva Pharmaceutical Industries an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote.

CompanyUnderperformOutperform
Organon & Co.Outperform Votes
16
33.33%
Underperform Votes
32
66.67%
Teva Pharmaceutical IndustriesOutperform Votes
1317
67.68%
Underperform Votes
629
32.32%

Organon & Co. presently has a consensus price target of $22.60, suggesting a potential upside of 7.72%. Teva Pharmaceutical Industries has a consensus price target of $18.56, suggesting a potential upside of 10.38%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Organon & Co..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organon & Co.
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
Teva Pharmaceutical Industries
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.78

Organon & Co. has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organon & Co.$6.26B0.86$1.02B$4.095.13
Teva Pharmaceutical Industries$15.85B1.20-$559M-$0.41-41.00

Organon & Co. has a net margin of 16.50% compared to Teva Pharmaceutical Industries' net margin of -2.88%. Teva Pharmaceutical Industries' return on equity of 37.33% beat Organon & Co.'s return on equity.

Company Net Margins Return on Equity Return on Assets
Organon & Co.16.50% -360.57% 9.15%
Teva Pharmaceutical Industries -2.88%37.33%6.73%

In the previous week, Teva Pharmaceutical Industries had 4 more articles in the media than Organon & Co.. MarketBeat recorded 7 mentions for Teva Pharmaceutical Industries and 3 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.32 beat Teva Pharmaceutical Industries' score of 0.91 indicating that Organon & Co. is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Organon & Co.
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Teva Pharmaceutical Industries
5 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 1.4% of Organon & Co. shares are owned by insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Teva Pharmaceutical Industries beats Organon & Co. on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OGN vs. The Competition

MetricOrganon & Co.Pharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$5.40B$7.06B$5.29B$18.23B
Dividend Yield5.34%2.70%2.81%3.48%
P/E Ratio5.1310.79125.3422.75
Price / Sales0.86278.522,168.1815.16
Price / Cash4.1832.1935.8320.01
Price / Book-77.705.734.865.06
Net Income$1.02B$147.21M$111.70M$974.25M
7 Day Performance-1.50%-2.42%-0.66%0.04%
1 Month Performance2.54%6.57%7.53%4.49%
1 Year Performance0.38%-4.24%4.27%7.07%

Organon & Co. Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TEVA
Teva Pharmaceutical Industries
3.4948 of 5 stars
3.49 / 5 stars
$16.38
-1.6%
$18.56
+13.3%
+96.4%$18.86B$15.85B-39.9537,851News Coverage
BGNE
BeiGene
2.5309 of 5 stars
2.53 / 5 stars
$153.64
+0.5%
$250.75
+63.2%
-19.9%$14.90B$2.46B-20.3010,600News Coverage
RDY
Dr. Reddy's Laboratories
0.4806 of 5 stars
0.48 / 5 stars
$78.70
+0.3%
$81.00
+2.9%
+23.4%$13.13B$3.35B19.5327,048Upcoming Earnings
News Coverage
CTLT
Catalent
2.4415 of 5 stars
2.44 / 5 stars
$58.09
+0.4%
$55.65
-4.2%
+25.0%$10.51B$4.28B-9.5217,800Analyst Forecast
News Coverage
Positive News
LNTH
Lantheus
3.5731 of 5 stars
3.57 / 5 stars
$121.61
+2.8%
$113.86
-6.4%
+30.9%$8.20B$1.30B18.57700Analyst Revision
News Coverage
RVMD
Revolution Medicines
2.894 of 5 stars
2.89 / 5 stars
$46.42
-0.7%
$50.50
+8.8%
+70.8%$7.72B$11.58M-12.38250Analyst Forecast
Insider Selling
Analyst Revision
News Coverage
ELAN
Elanco Animal Health
4.1838 of 5 stars
4.18 / 5 stars
$13.05
-1.5%
$17.57
+34.6%
+7.5%$6.45B$4.42B-4.929,300
SMMT
Summit Therapeutics
2.0895 of 5 stars
2.09 / 5 stars
$9.31
+2.1%
$13.50
+45.0%
+316.4%$6.40B$700,000.00-58.19110Positive News
Gap Up
KRYS
Krystal Biotech
4.1728 of 5 stars
4.17 / 5 stars
$207.30
-0.6%
$177.63
-14.3%
+61.5%$5.92B$50.70M110.86210Analyst Revision
News Coverage
Positive News
APLS
Apellis Pharmaceuticals
4.1389 of 5 stars
4.14 / 5 stars
$39.49
-4.0%
$74.75
+89.3%
-6.2%$4.79B$396.59M-11.41770Analyst Forecast
Short Interest ↑
Analyst Revision
News Coverage

Related Companies and Tools

This page (NYSE:OGN) was last updated on 7/20/2024 by MarketBeat.com Staff

From Our Partners